Skip to main content

Advertisement

SpringerLink
Log in

Pentraxins, Anti-pentraxin Antibodies, and Atherosclerosis

  • Published:
Clinical Reviews in Allergy & Immunology Aims and scope Submit manuscript

Abstract

Atherosclerosis is a disease of the vascular wall, which predominantly affects large and medium-sized arteries. It represents a leading cause of morbidity and mortality in the Western world. In the last few decades, it has been clearly shown that immune system plays a relevant role in atherogenesis. The effectors of both innate and adaptive immunity, including immune cells, cell or soluble receptors, cytokines, chemokines, complement components or coagulation systems, and autoantibodies are able to modulate atherosclerosis. Among proteins belonging to innate immunity, the highly conserved pentraxin family, which encompass C-reactive protein (CRP), serum amyloid P (SAP), and the long pentraxin 3 (PTX3) seems to be directly involved in the induction and progression of atherosclerosis. By immunohistochemical staining, pentraxins were found within the atherosclerotic plaques where they could play a key role interacting with atherogenic-modified lipoproteins, favoring the formation of foam cells, and exerting a proinflammatory action. Pentraxin serum levels have been shown to be associated with clinical and subclinical atherosclerosis in general population. Antibodies against pentraxins have been demonstrated in patients with autoimmune diseases, but their role in atherogenesis is still controversial.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ross R (1999) Atherosclerosis-an inflammatory disease. N Engl J Med 340:115–126

    Article  PubMed  CAS  Google Scholar 

  2. Hansson GK (2002) Innate and adaptive immunity in the pathogenesis of atherosclerosis. Cir Res 91:281–291

    Article  CAS  Google Scholar 

  3. Hansson GK, Libby P (2006) The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol 6:508–518

    Article  PubMed  CAS  Google Scholar 

  4. Hansson GK (2005) Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352:1685–1695

    Article  PubMed  CAS  Google Scholar 

  5. Shoenfeld Y, Sherer Y, Harats D (2001) Atherosclerosis as an infectious, inflammatory and autoimmune disease. Trends Immunol 22:293–295

    Article  PubMed  CAS  Google Scholar 

  6. Doria A, Shoenfeld Y, Wu R, Gambari PF, Puato M, Ghirardello A et al (2003) Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus. Ann Rheum Dis 62:1071–1077

    Article  PubMed  CAS  Google Scholar 

  7. Shoenfeld Y, Gerli R, Doria A, Matsuura E, Cerinic MM, Ronda N et al (2005) Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 112:3337–3347

    Article  PubMed  Google Scholar 

  8. Frostegard J (2005) Atherosclerosis in patients with autoimmune disorders. Artherioscler Thromb Vasc Biol 25:1776–1785

    Article  CAS  Google Scholar 

  9. Doria A, Sherer Y, Meroni PL, Shoenfeld Y (2005) Inflammation and accelerated atherosclerosis: basic mechanisms. Rheum Dis Clin North Am 31:355–362

    Article  PubMed  Google Scholar 

  10. Nilsson J, Hansson GK (2008) Autoimmunity in atherosclerosis: a protective response losing control? J Intern Med 263:464–478

    Article  PubMed  CAS  Google Scholar 

  11. Bassi N, Ghirardello A, Iaccarino L, Zampieri S, Rampudda ME, Atzeni F et al (2007) OxLDL/β2GPI-anti-oxLDL/β2GPI complex and atherosclerosis in SLE patients. Autoimmun Rev 7:52–58

    Article  PubMed  CAS  Google Scholar 

  12. Szyper Kravitz M, Pitashny M, Shoenfeld Y (2005) Protective molecules—C-reactive protein (CRP), serum amyloid P (SAP), Pentraxin3 (PTX3), mannose-binding lectin (MBL), and apolipoprotein A1 (ApoA1), and their autoantibodies: prevalence and clinical significance in autoimmunity. J Clin Immunol 25:582–591

    Article  CAS  Google Scholar 

  13. Szyper Kravitz M, Shoenfeld Y (2006) Autoimmunity to protective molecules: is it the perpetuum mobile (vicious cycle) of autoimmune rheumatic diseases? Nat Clin Pract Rheumatol 2:481–490

    Article  CAS  Google Scholar 

  14. Kobayashi K, Tada K, Itabe H, Ueno T, Liu PH, Tsutsumi A et al (2007) Distinguished effect of antiphospholipid antibodies and anti-oxidized LDL antibodies on oxidized LDL uptake by macrophages. Lupus 16:929–938

    Article  PubMed  CAS  Google Scholar 

  15. Shishehbor MH, Bhatt DL (2004) Inflammation and atherosclerosis. Curr Atheroscler Rep 6:131–139

    Article  PubMed  Google Scholar 

  16. Gordon PA, George J, Khamatshta M, Harats D, Hughes G, Shoenfeld Y (2001) Atherosclerosis and autoimmunity. Lupus 10:249–252

    Article  PubMed  CAS  Google Scholar 

  17. Tedesco F, Fischetti F, Pausa M, Dobrina A, Sim RB, Daha MR (1999) Complement-endothelial cell interactions: pathophysiological implications. Mol Immunol 36:261–268

    Article  PubMed  CAS  Google Scholar 

  18. Ando B, Wiedmer T, Hamilton KK, Sims PJ (1988) Complement proteins C5b-9 initiate secretion of platelet storage granules without increased binding of fibrinogen or von Willebrand factor to newly expressed cell surface GPIIb-IIIa. J Biol Chem 263:11907–11914

    PubMed  CAS  Google Scholar 

  19. Thorbjornsdottir P, Kolka R, Gunnarsson E, Bambir SH, Thorgeirsson G, Kotwal GJ et al (2005) Vaccinia virus complement control protein diminishes formation of atherosclerotic lesions: complement is centrally involved in atherosclerotic disease. Ann NY Acad Sci 1056:1–15

    Article  PubMed  CAS  Google Scholar 

  20. Pauletto P, Puato M, Faggin E, Santipolo N, Pagliara V, Zoleo M et al (2000) Specific cellular features of atheroma associated with development of neointima after carotid endrterectomy: the carotid atherosclerosis and restenosis study. Circulation 102:771–778

    PubMed  CAS  Google Scholar 

  21. Taleb S, Tedgui A, Mallat Z (2008) Regulatory T-cell immunity and its relevance to atherosclerosis. J Intern Med 263:489–499

    Article  PubMed  CAS  Google Scholar 

  22. Szabo SJ, Sullivan BM, Peng SL, Glimcher LH (2003) Molecular mechanism regulating Th1 immune responses. Annu Rev Immunol 21:713–758

    Article  PubMed  CAS  Google Scholar 

  23. Cheng X, Yu X, Ding YI, Fu Q, Xie J, Tang T et al (2008) The Th17/Treg imbalance in patients with acute coronary sindrome. Clin Immunol 127:89–97

    PubMed  CAS  Google Scholar 

  24. Liuzzo G, Kopecky SL, Frye RL, O’Fallon WM, Maseri A, Goronzy JJ et al (1999) Perturbation of the T-cells repertoire in patients with unstable angina. Circulation 100:2135–2139

    PubMed  CAS  Google Scholar 

  25. Warrington KJ, Vallejo AN, Weyand CM, Goronzy JJ (2003) CD28 loss in senescent CD4+T cells: reversal by interleukin-12 stimulation. Blood 101:3543–3549

    Article  PubMed  CAS  Google Scholar 

  26. Gerli R, Schillaci G, Giordano A, Bocci EB, Bistoni O, Vando G et al (2004) CD4+CD28-T lymphocytes contribute to early atherosclerotic damage in rheumatoid arthritis patients. Circulation 109:2744–2748

    Article  PubMed  CAS  Google Scholar 

  27. Lehtimäki T, Lehtinen S, Solakivi T, Nikkilä M, Joakkola O, Jokela H et al (1999) Autoantibodies against oxidized low density lipoprotein in patients with angiographically verified coronary artery disease. Artherioscler Thromb Vasc Biol 19:23–27

    Google Scholar 

  28. George J, Harats D, Bakshi E, Adler Y, Levy Y, Gilburd B et al (1999) Anti-oxidized low density lipoprotein antibodiy determination as a predictor of restenosis following percutaneous transluminal coronary angioplasty. Immunol Lett 68:263–266

    Article  PubMed  CAS  Google Scholar 

  29. George J, Afek A, Gilburd B, Levkovitz H, Shaish A, Goldberg I et al (1998) Hyperimmunization of apo-E-deficient mice with homologous malondialdehyde low-density lipoprotein suppresses early atherogenesis. Atherosclerosis 138:147–152

    Article  PubMed  CAS  Google Scholar 

  30. Ameli S, Hulgtgardh-Nilsso A, Regnström J, Calara F, Yano J, Crcek B et al (1996) Effect of immunization with homologous LDL and oxidized on early atherosclerosis in hypercholesterolemic rabbits. Artherioscler Thromb Vasc Biol 16:1074–1079

    CAS  Google Scholar 

  31. Matsuura E, Kobayashi K, Inoue K, Lopez LR, Shoenfeld Y (2005) Oxidized LDL/beta2-glycoprotein I complexes: new aspects in atherosclerosis. Lupus 14:736–741

    Article  PubMed  CAS  Google Scholar 

  32. Koike T, Ichikawa K, Kasahara H, Atsumi T, Tsutsumi A, Matsuura E (1998) Epitopes on beta2-GPI recognized by anticardiolipin antibodies. Lupus 7:S14–S17

    Article  PubMed  CAS  Google Scholar 

  33. George J, Harats D, Gilburd B, Afek A, Levy Y, Schneidermen J et al (1999) Immunolocalization of beta2-glycoprotein I (apolipoprotein H) to human atherosclerotic plaques: potential implication for lesion progression. Circulation 99:2227–2230

    PubMed  CAS  Google Scholar 

  34. George J, Shoenfeld Y, Harats D (1999) The involvement of beta2-glycoprotein I (beta2-GPI) in human and murin atherosclerosis. J Autoimmun 13:57–60

    Article  PubMed  CAS  Google Scholar 

  35. Sherer Y, Shemesh J, Tenenbaum A, Praprotnik S, Harats D, Fisman EZ, Blank M et al (2000) Coronary calcium and anti-cardiolipin antibody are elevated in patients with typical chest pain. Am J Cardiol 86:1306–1311

    Article  PubMed  CAS  Google Scholar 

  36. Sherer Y, Tenenbaum A, Praprotnik S, Shemesh J, Blank M, Fisman EZ et al (2001) Coronary artery disease but not coronary calcification is associated with elevated levels of cardiolipin, beta-2-glycoprotein-I, and oxidized LDL antibodies. Cardiology 95:20–24

    Article  PubMed  CAS  Google Scholar 

  37. Mandal K, Foteinos G, Jahangiri M Xu Q (2005) Role of antiheat shock protein 60 autoantibodies in atherosclerosis. Lupus 14:742–746

    Article  PubMed  CAS  Google Scholar 

  38. Garlanda C, Bottazzi B, Bastone A, Mantovani A (2005) Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu Rev Immunol 23:337–366

    Article  PubMed  CAS  Google Scholar 

  39. Mantovani A, Garlanda C, Doni A, Bottazzi B (2008) Pentraxins in innate immunity: from C-reactive protein to the long pentraxin PTX3. J Clin Immunol 28:1–13

    Article  PubMed  CAS  Google Scholar 

  40. Thompson D, Pepys MB, Wood SP (1999) The physiological structure of human C-reactive protein and its complex with phosphocholine. Structure 7:169–177

    Article  PubMed  CAS  Google Scholar 

  41. Du Clos TW, Mold C (2004) C-reactive protein. An activator of innate immunity and a modulator of adaptive immunity. Immunol Res 30:261–277

    Article  PubMed  CAS  Google Scholar 

  42. Patel DN, King CA, Bailey SR, Holt JW, Venkatachalam K, Agrawal A et al (2007) Interleukin-17 stimulates C-reactive protein expression in hepatocytes and smooth muscle cells via p38 MAPK and ERK1/2-dependent NF-kB and C/EBPβ activation. J Biol Chem 282:27229–27238

    Article  PubMed  CAS  Google Scholar 

  43. Pepys MB, Hirschfield GM (2003) C-reactive protein: a critical update. J Clin Invest 111:1805–1812

    PubMed  CAS  Google Scholar 

  44. Szalai AJ (2002) The antimicrobial activity of C-reactive protein. Microbes Infect 4:201–205

    Article  PubMed  CAS  Google Scholar 

  45. Du Clos (1996) The interaction of C-reactive protein and serum amyloid P component with nuclear antigens. Med Biol Res 23:253–260

    CAS  Google Scholar 

  46. Gershov D, Kim SJ, Brot N, Elkon KB (2000) C-reactive protein binds to apoptotic cells, protects the cells from assembly of the terminal complement components, and sustain anti-inflammatory innate immune response: implication for systemic autoimmunity. J Exp Med 192:1353–1363

    Article  PubMed  CAS  Google Scholar 

  47. Khreiss T, Jozsef L, Potempa LA, Filep JG (2004) Conformational rearrangement in C-reactive protein is required for proinflammatory actions on human endothelial cells. Circulation 109:2016–2022

    Article  PubMed  CAS  Google Scholar 

  48. Ridker PM, Hennekens CH, Buring JE, Rifai N (2000) C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 342(12):836–843

    Article  PubMed  CAS  Google Scholar 

  49. Aukrust P, Halvorsen B, Yndestad A, Ueland T, Øie E, Otterdal K et al (2008) Chemokines and cardiovascular risk. Artherioscler Thromb Vasc Biol (in press)

  50. Morrow DA, de Lemos JA, Sabatine MS, Wiviot SD, Blazing MA, Shui A et al (2006) Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocol Trial. Circulation 114:281–288

    Article  PubMed  CAS  Google Scholar 

  51. Morrow DA, Rifai N, Antman EM, Weiner DN, McCabe CH, Cannon CP et al (1998) C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy Thrombolysis in Myocardial Infarction. J Am Coll Cardiol 31:1460–1465

    Article  PubMed  CAS  Google Scholar 

  52. Engström G, Hedblad B, Tydén P, Lindgärde F (2008) Inflammation-sensitive plasma proteins are associated with increased incidence of heart failure: a population-based cohort study. Atherosclerosis (in press)

  53. Rosenau BJ, Costenbader KH, Schur PH (2008) C-reactive protein, anti-C-reactive protein antibodies and clinical atherosclerosis. Vasc Med 13:25–28

    Article  PubMed  Google Scholar 

  54. Manfredi AA, Rovere-Querini P, Bottazzi B, Garlanda C, Mantovani A (2008) Pentraxins, humoral innate immunity and tissue injury. Curr Opin Immunol 20:1–7

    Article  CAS  Google Scholar 

  55. Torzewski J, Torzewski M, Bowyer DE, Frohlich M, Koenig W, Waltenberger J et al (1998) C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesion of human coronary arteries. Artherioscler Thromb Vasc Biol 18:1386–1392

    CAS  Google Scholar 

  56. Zhang YX, Cliff WJ, Schoefl GI, Higgins G (1999) Coronary C-reactive protein distribution: its relation to development of atherosclerosis. Atherosclerosis 145:375–379

    Article  PubMed  CAS  Google Scholar 

  57. Kovacs A, Tornvall P, Nilsson R, Tegnér J, Hamsten A, Björkegren J (2007) Human C-reactive protein slows atherosclerosis development in a mouse model with human-like hypercholesterolemia. Proc Natl Acad Sci U S A 104:13768–13773

    Article  PubMed  CAS  Google Scholar 

  58. Tennent GAA, Hutchinson WL, Kahan MC, Hirscfield GM, Gallimore JR, Lewin J et al (2008) Transgenic human CRP is not pro-atherogenic, pro-atherothrombotic or pro-inflammatory in apoE-/- mice. Atherosclerosis 196:248–255

    Article  PubMed  CAS  Google Scholar 

  59. Singh U, Devaraj S, Vasquez-Vivar J, Jialal I (2007) C-reactive protein decreases endothelial nitric oxide synthase activity via uncoupling. J Mol Cell Cardiol 43:780–791

    Article  PubMed  CAS  Google Scholar 

  60. Ryu J, Lee CW, Shin JA, Park CS, Kim JJ, Park SJ et al (2007) Fcgamma RIIa mediates C-reactive protein-induced inflammatory responses of human vascular smooth muscle cells by activating NADPH oxidase 4. Cardiovasc Res 75:555–565

    Article  PubMed  CAS  Google Scholar 

  61. Singh U, Dasu MR, Yancey PG, Afify A, Devaraj S, Jialal I (2008) Human C-reactive protein promotes oxidized low-density lipoprotein uptake and matrix metalloproteinase-9 release in Wistar rats. J Lipid Res 49:1015–1023

    Article  PubMed  CAS  Google Scholar 

  62. Devaraj S, Dasu MR, Singh U, Rao LVM, Jialal I (2008) C-reactive protein stimulates superoxide anion release and tissue factor activity in vivo. Atherosclerosis (in press)

  63. Taskinen S, Hyvönen M, Kovanen PT, Meri S, Pentikäinen MO (2005) C-reactive protein binds to 3β-OH group of cholesterol in LDL particles. Biochem Biophys Res Commun 329:1208–1216

    Article  PubMed  CAS  Google Scholar 

  64. Bhakdi S, Torzewski M, Paprotka K, Schmitt S, Barssom H, Suriyaphol P et al (2004) Possible protective roel for C-reactive protein in atherogenesis. Complement activation by modified lipoproteins halts before detrimental sequence. Circulation 109:1870–1876

    Article  PubMed  CAS  Google Scholar 

  65. Pepys MB, Rademacher TW, Amatayakul-Chantler S, Williams P, Noble GE, Hutchinson WL et al (1994) Human serum amyloid P component is an invariant costituent of amyloid deposits and has a uniquely homogeneous glycostructure. Proc Natl Acad Sci U S A 91:5602–5606

    Article  PubMed  CAS  Google Scholar 

  66. Hutchinson WL, Hohenester E, Pepys MB (2000) Human serum amyloid P component is a single uncomplexed pentamer in whole serum. Mol Med 6:482–493

    PubMed  CAS  Google Scholar 

  67. Lin BF, KU NO, Zahedi K, Whitehead AS, Mortensen RF (1990) IL-1 and IL-6 mediate increased production and synthesis by hepatocytes of acute-phase serum amyloid P-component (SAP). Inflammation 14:297–313

    Article  PubMed  CAS  Google Scholar 

  68. Hamazaki H (1995) Ca(2+)-dependent binding of human serum amyloid P component to Alzheimer’s beta-amyloid peptide. J Biol Chem 270:10392–10394

    PubMed  CAS  Google Scholar 

  69. Koenig W (2007) Serum amyloid P component and cardiovascular disease. Is there a sensible link? Artherioscler Thromb Vasc Biol 27:698–700

    Article  CAS  Google Scholar 

  70. Jenny NS, Arnold AM, Kuller LH, Tracy RP, Psaty BM (2007) Serum amyloid P and cardiovascular disease in older men and women. Results from the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol 27:352–358

    Article  PubMed  CAS  Google Scholar 

  71. Noursadeghi M, Bickerstaff MC, Galimore JR, Herbert J, Cohen J, Pepys MB (2000) Role of serum amyloid P component in bacteria infection: protection of the host or protection of the pathogen. Proc Natl Acad Sci U S A 97:14584–14589

    Article  PubMed  CAS  Google Scholar 

  72. Rocken C, Tautenhahn J, Buhling F, Sachwitz D, Vockler S, Goette A et al (2006) Prevalence and pathology of amyloid in atherosclerotic arteries. Artherioscler Thromb Vasdc Biol 26:676–677

    Article  CAS  Google Scholar 

  73. Myers SL, Jones S, Janh TR, Morten IJ, Tennent GA, Hewitt EW et al (2006) A systemic study of the effect of physiological factors on beta2-microglobulin amyloid formation at neutral pH. Biochemistry 45:2311–2321

    Article  PubMed  CAS  Google Scholar 

  74. Mac Rail CA, Stewart CR, Mok YF, Gunzburg MJ, Perugini MA, Lawrence LJ et al (2004) Non-fibrillar components of amyloid deposits mediates the self-association and tangling of amyloid fibrils. J Biol Chem 279:21038–21045

    Article  CAS  Google Scholar 

  75. Pilling D, Tucker NM, Gomer RH (2006) Aggregated IgG inhibits the differentiation of of human fibrocytes. J Leucok Biol 79(6):1242–1251

    Article  CAS  Google Scholar 

  76. Stewart CR, Tseng AA, Mok YF, Staples MK, Schiesser CH, Lawrence LJ et al (2005) Oxidation of low-density lipoproteins induces amyloid like structures that are recognized by macrophages. Biochemistry 44:9108–9116

    Article  PubMed  CAS  Google Scholar 

  77. Breviario F, d’Aniello EM, Golay J, Peri G, Bottazzi B, Bairoch A et al (1992) Interleukin-1-inducible genes in endothelial cells. Cloning of a new gene related to C-reactive protein and serum amyloid P component. J Biol Chem 267(31):22190–22197

    PubMed  CAS  Google Scholar 

  78. Bottazzi B, Vouret-Craviari V, Bastone A, De Gioia L, Matteucci C, Peri G et al (1997) Multimer formation and ligand recognition by the long pentraxin PTX3. J Biol Chem 272:32817–32823

    Article  PubMed  CAS  Google Scholar 

  79. Muller B, Peri G, Doni A, Torri V, Landmann R, Bottazzi B et al (2001) Circulating levels of the long pentraxin PTX3 correlate with severity of infection in critically ill patients. Crit Care Med 29:1404–1407

    Article  PubMed  CAS  Google Scholar 

  80. Ortega-Hernandez OD, Bassi N, Shoenfeld Y, Anaya JM (2008) The long pentraxin 3 and its role in autoimmunity. Semin Arthritis Rheum (in press)

  81. Mantovani A, Garlanda C, Bottazzi B (2003) Pentraxin3, a non-redundant soluble pattern recognition receptor involved in innate immunity. Vaccine 21:S43–S47

    Article  PubMed  CAS  Google Scholar 

  82. Nauta AJ, Bottazzi B, Mantovani A, Salvatori G, Kishore U, Schwaeble WJ et al (2003) Biochemical and functional characterization of the interaction between pentraxin 3 and C1q. Eur J Immunol 33:465–473

    Article  PubMed  CAS  Google Scholar 

  83. van Rossum AP, Fazzini F, Limburg PC, Manfredi AA, Rovere-Querini P, Mantovani A et al (2004) The prototypic tissue pentraxin PTX3, in contrast to the short pentraxin serum amyloid P, inhibits phagocytosis of late apoptotic neutrophils by macrophages. Arthritis Rheum 50:2667–2674

    Article  PubMed  CAS  Google Scholar 

  84. Baruah P, Dumitriu IE, Peri G, Russo V, Mantovani A, Manfredi AA et al (2006) The tissue pentraxin PTX3 limits C1q-mediated complement activation and phagocytosis of apoptotic cells by dendritic cells. J Leukoc Biol 80(1):87–95

    Article  PubMed  CAS  Google Scholar 

  85. Napoleone E, Di Santo A, Bastone A, Peri G, Mantovani A, de Gaetano G et al (2002) Long pentraxin PTX3 upregulates tissue factor expression in human endothelial cells: a novel link between vascular inflammation and clotting activation. Artherioscler Thromb Vasc Biol 22:782–787

    Article  CAS  Google Scholar 

  86. Napoleone E, Di Santo A, Bastone A, Peri G, Mantovani A, de Gaetano G et al (2004) The long pentraxin PTX3 up-regulates tissue factor in activated monocytes: another link between inflammation and clotting activation. J Leukoc Biol 76:203–209

    Article  PubMed  CAS  Google Scholar 

  87. Peri G, Introna M, Corradi D, Iacuitti G, Signorini S, Avanzini F et al (2000) PTX3, a prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans. Circulation 102:636–641

    PubMed  CAS  Google Scholar 

  88. Latini R, Maggioni AP, Peri G, Gonzini L, Lucci D, Mocarelli P et al (2004) Lipis Assessment Trial Italian Network (LATIN) Investigators. Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. Circulation 110:2349–2354

    Article  PubMed  CAS  Google Scholar 

  89. Suzuki S, Takeishi Y, Niizeki T, Koyama Y, Kitahara T, Sasaki T et al (2008) Pentraxin 3, a new marker for vascular inflammation, predicts adverse clinical outcomes in patients with heart failure. Am Heart J 155:75–81

    Article  PubMed  CAS  Google Scholar 

  90. Rolph MS, Zimmer S, Bottazzi B, Garlanda C, Mantovani A, Hansson GK (2002) Production of the long pentraxin PTX3 in advanced atherosclerotic plaques. Arterioscler Thromb Vasc Biol 22:10–14

    Article  Google Scholar 

  91. Savchenko AS, Imamura M, Ohashi R, Jiang S, Kawasaki T, Hasegawa G et al (2008) Expression of pentraxin 3 (PTX3) in human atherosclerotic lesions. J Pathol 215:48–55

    Article  PubMed  CAS  Google Scholar 

  92. Klouche M, Peri G, Knabbe C, Eckstein HH, Schmid FX, Schmitz G et al (2004) Modified atherogenic lipoproteins induce expression of pentraxin-3 by human vascular smooth muscle cells. Atherosclerosis 175:221–228

    Article  PubMed  CAS  Google Scholar 

  93. Sjowall C, Eriksson P, Almer S, Skogh T (2002) Autoantibodies to C-reactive protein is a common finding in SLE, but not in primary Sjogren syndrome, rheumatoid arthritis or inflammatory bowel disease. J Autoimmun 19:155–160

    Article  PubMed  Google Scholar 

  94. Sjowall C, Bengtsson AA, Sturfel G, Skogh T (2004) Serum levels of autoantibodies against monomeric C-reactive protein are correlated with disease activity in systemic lupus erythematosus. Arthritis Res Ther 6:R87–R94

    Article  PubMed  CAS  Google Scholar 

  95. Zandman-Goddard G, Blank M, Langevitz P, Slutsky L, Pras M, Levy Y et al (2005) Anti-serum amyloid P (SAP) antibodies in SLE patients correlate with the disease activity. Ann Rheum Dis 64:1698–1702

    Article  PubMed  CAS  Google Scholar 

  96. Figueredo MA, Rodriguez A, Ruiz-Yague M, Romero M, Fernandez-Cruz A, Gomez-de la Concha E et al (2006) Autoantibodies against C-reactive protein: clinical associations in systemic lupus erythematosus and primary antiphospholipid syndrome. J Rheumatol 33:1980–1986

    PubMed  CAS  Google Scholar 

  97. Bassi N, Ghirardello A, Zampieri S, Rampudda M, Atzeni F, Sarzi-Puttini P et al (2008) Anti-PTX3: are they real? Clin Exp Rheumatol 26(Suppl 48):S–89

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Rheumatology, Department of Medical and Surgical Sciences, University of Padova, Via Giustiniani, 2, 35128, Padova, Italy

    N. Bassi, S. Zampieri, A. Ghirardello, M. Tonon, M. Zen, F. Cozzi & A. Doria

Authors
  1. N. Bassi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Zampieri
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Ghirardello
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Tonon
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. Zen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. F. Cozzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A. Doria
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. Doria.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bassi, N., Zampieri, S., Ghirardello, A. et al. Pentraxins, Anti-pentraxin Antibodies, and Atherosclerosis. Clinic Rev Allerg Immunol 37, 36–43 (2009). https://doi.org/10.1007/s12016-008-8098-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12016-008-8098-6

Keywords

Search

Navigation